Therapeutic effect of arotinolol on chronic heart failure and its influence on plasma BNP level / 心血管康复医学杂志

ABSTRACT

Objective:To study therapeutic effect of arotinolol hydrochloride on chronic heart failure (CHF) and its influence on plasma levels of brain natriuretic peptide (BNP).Methods:A total of 116 CHF patients treated in our hospital were selected,randomly and equally divided into routine treatment group and arotinolol group (received arotinolol based on routine treatment ),both groups were continuously treated for six months.Left ventricular end-systolic volume (LVESV ),left ventricular end-diastolic volume (LVEDV ),left ventricular ejection fraction (LVEF),myocardial energy expenditure (MEE),serum levels of interleukin (IL)-8 and high sensitive C reactive protein (hsCRP),plasma BNP level,Lee heart failure score and incidence of adverse reactions were observed and compared between two groups before and after treatment.Results:Compared with routine treatment group after treatment,there were significant reductions in LVESV [ (38.45 ± 3.93) ml vs.(36.42 ± 3.51) ml],LVEDV [ (49.23 ± 4.89) ml vs.(47.43 ± 4.37) ml],MEE [ (96.11 ± 9.86) cal/min vs.(86.58 ± 8.83) cal/min],levels of IL-8 [ (32.18 ± 3.17) ng/L vs.(28.92 ± 2.79) ng/L],hsCRP [ (5.86 ± 0.51) mg/L vs.(3.78 ± 0.35) mg/L],BNP [ (275.75 ± 27.64) ng/L vs.(196.75 ± 20.04) ng/L] and Lee heart failure score [ (4.77 ± 0.73) scores vs.(2.82 ± 0.54) scores],and significant rise in LVEF [ (45.69 ± 4.76)% vs.(51.89 ± 5.30)%] in arotinolol group,P＜0.05 or ＜0.01.Total effective rate of arotinolol group was significantly higher than that of routine treatment group (94.83% vs.79.31%,P＝0.027).There were no obvious adverse reactions in two groups during treatment.Conclusion:Arotinolol can significantly improve heart function,reduce plasma BNP and inflammatory factor levels in CHF patients.The therapeutic effect is significant,and it＇s safe and reliable.